tbuckley/cabot-search huggingface dataset:
Higher Rates of Death and Major Bleeding Highlight the Inequities That Exist in the Care of People with Venous Thromboembolism Who Experience Social Exclusion: Findings from a Prospective Registry of 79735 Patients (RIETE)
Authors: Karl Ewins, Fionnuala Ni Ainle, Cliona Ni Cheallaigh, Eoghan Dunlea, Sarah Kelliher, Egidio Imbalzano, Cristiano Bortoluzzi, Inés Jou, Joaquín Alfonso-Megido, María del Carmen Díaz-Pedroche, Manuel Monreal
Journal: Blood (2019)
Annals Story Slam - Hours to Days
Authors: Jonah Himelfarb
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - Hours to DaysFREEJonah Himelfarb, MDJonah Himelfarb, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0025 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Hours to Days "Hours to Days," by Jonah Himelfarb, MD (Duration 5:53)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways
Authors: Nicole Kucine, Amanda R. Leonti, Aishwarya Krishnan, Rhonda E. Ries, Ross L. Levine, Soheil Meshinchi
Journal: Blood (2019)
Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide
Authors: Kentaro Ido, Hideo Koh, Hiroshi Okamura, Shiro Koh, Satoru Nanno, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae
Journal: Blood (2019)
Is 4400 Steps per Day the New 10 000 Steps per Day?
Authors: Elroy J. Aguiar, Scott W. Ducharme, Diana M. Thomas
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Man in Relation to His Environment
Authors: F. Marsh
Journal: BMJ (1946)

<h3>Abstract</h3> <h3>Background</h3> SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) testing remains the cornerstone of laboratory-based identification of patients with COVID-19. As the availability and speed of SARS-CoV-2 testing platforms improve, results are increasingly relied upon to inform critical decisions related to therapy, use of personal protective equipment, and workforce readiness. However, early reports of RT-PCR test performance have left clinicians and the public with concerns regarding the reliability of this predominant testing modality and the interpretation of negative results. In this work, two independent research teams report the frequency of discordant SARS-CoV-2 test results among initially negative, repeatedly tested patients in regions of the United States with early community transmission and access to testing. <h3>Methods</h3> All patients at the University of Washington (UW) and Stanford Health Care undergoing initial testing by nasopharyngeal (NP) swab between March 2nd and April 7th, 2020 were included. SARS-CoV-2 RT-PCR was performed targeting the <i>N, RdRp, S</i>, and <i>E</i> genes and ORF1ab, using a combination of Emergency Use Authorization laboratory-developed tests and commercial assays. Results through April 14th were extracted to allow for a complete 7-day observation period and an additional day for reporting. <h3>Results</h3> A total of 23,126 SARS-CoV-2 RT-PCR tests (10,583 UW, 12,543 Stanford) were performed in 20,912 eligible patients (8,977 UW, 11,935 Stanford) undergoing initial testing by NP swab; 626 initially test-negative patients were re-tested within 7 days. Among this group, repeat testing within 7 days yielded a positive result in 3.5% (4.3% UW, 2.8% Stanford) of cases, suggesting an initial false negative RT-PCR result; the majority (96.5%) of patients with an initial negative result who warranted reevaluation for any reason remained negative on all subsequent tests performed within this window. <h3>Conclusions</h3> Two independent research teams report the similar finding that, among initially negative patients subjected to repeat SARS-CoV-2 RT-PCR testing, the occurrence of a newly positive result within 7 days is uncommon. These observations suggest that false negative results at the time of initial presentation do occur, but potentially at a lower frequency than is currently believed. Although it is not possible to infer the clinical sensitivity of NP SARS-CoV-2 RT-PCR testing using these data, they may be used in combination with other reports to guide the use and interpretation of this common testing modality.
How Can We Routinely Measure Appropriateness of Antimicrobial Use in Hospitals at a National Level?
Authors: Céline Pulcini, Marlies Hulscher
Journal: JAMA Network Open (2019)

The study by Ierano et al1 presents the results of a national audit assessing the appropriateness of surgical antimicrobial prophylaxis (SAP) in Australia. This well-designed and ambitious initiative provides data for action to guide antimicrobial stewardship (AMS) interventions.
A Modified CALGB-10403 in Hispanic Adolescent and Young Adults with Philadelphia -Negative Acute Lymphoblastic Leukemia: Promising Results Despite a High-Rate of Metabolic and Hepatic Toxicities
Authors: Juan Rangel-Patiño, Alvaro Cabrero Garcia, Carolina Balderas-Delgado, Lauro Fabian Amador, Yvette Neme Yunes, Ana Cooke, Adriana Rosas, Roberta Demichelis
Journal: Blood (2019)
Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed By Newborn Screening: A Real-World Nation-Wide Study in France
Authors: Valentine Brousse, Cécile Arnaud, Emmanuelle Lesprit, Marie-Helene Odièvre-Montanié, Maryse Etienne-Julan, Gisele Elana, Marie Belloy, Cecile Dumesnil, Beatrice Quinet, Abdourahim Chamouine, Cecile Guillaumat, Nathalie Garnier, Corinne Pondarré, Nathalie Couque, Francoise Bernaudin, Mariane de Montalembert, Emmanuelle Boutin, Malika Benkerrou, Isabelle Thuret
Journal: Blood (2019)
NCMP-14. EEG FEATURES THAT INDEPENDENTLY ASSOCIATE WITH HIGHER GRADE NEUROTOXICITY IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
Authors: David Mao, Ivan Kotchetkov, Anne Reiner, Katherine Panageas, Xi Chen, Edward Avila, Bianca Santomasso
Journal: Neuro-Oncology (2019)

Abstract RATIONALE CAR T cell therapy has emerged as a promising treatment of refractory or relapsed leukemia and lymphoma. It is associated with severe side effects, such as immune effector cell-associated neurotoxicity syndrome (ICANS). Electroencephalography (EEG) is often performed in these patients as part of an evaluation of their altered mental status. We hypothesize certain EEG features are associated with high ICANS grade. METHODS Retrospective review of medical records was performed. From February 2010 through June 2016, 53 adults with relapsed B-cell acute lymphoblastic leukemia received 19-28z CAR T cells at MSKCC as part of a phase 1 trial. We identified patients from this group who were monitored with video EEG and recorded daily EEG features. A multivariable generalized estimating equation model was used to identify EEG findings that were independently associated with high ICANS grade (3 or 4). A Cox model was used to associate initial EEG findings with development of high ICANS grade. RESULTS There were 27 unique patients with a combined 109 days of video EEGs. In a multivariable model, lack of posterior dominant rhythm (PDR) (Odds Ratio (OR)=12.49, p&lt; .0001) and discontinuity (OR=9.50, p=0.01) were independently statistically significantly associated with high ICANS grade and generalized sharps retained marginal statistical significance (OR=4.77, p=0.06). Presence of state changes, focal slowing, generalized slowing, and epileptic discharges did not have statistically significant association. No EEG findings on initial day of monitoring was statistically significantly associated with eventual development of high ICANS grade. CONCLUSIONS EEG discontinuity and lack of PDR were associated with high severity of neurotoxicity. There may be clinical utility in monitoring for specific features when assessing for development or resolution of ICANS, but additional prospective studies employing EEG in patients receiving CAR T cell therapy are necessary.
Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience
Authors: Giovanni Caocci, Maria Pina Simula, Silvia Ghiani, Olga Mulas, Giorgia Mainas, Sandra Atzeni, Martina Pettinau, Emilio Usala, Giorgio La Nasa
Journal: Blood (2019)
Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Authors: Sikander Ailawadhi, Aneel Paulus, Victoria R. Alegria, Betsy Laplant, Muhamad Alhaj Moustafa, Dustin Chapin, Keisha Jackson, Prachi Jani, Salman Ahmed, Brett Edwards, Alak Manna, Vivek Roy, Taimur Sher, Asher A. Chanan-Khan
Journal: Blood (2019)
IMMU-02. NEOANTIGENS ARISING FROM ALTERNATIVE SPLICING EVENTS MAY BE TARGETED BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMAS
Authors: Alexander Lee, Yang Pan, Aaron Mochizuki, Mildred Galvez, Frances Chow, David Nathanson, Anthony Wang, Richard Everson, Linda Liau, Yi Xing, Robert Prins
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Alternative splicing, the cellular process that converts premature mRNA to mature mRNA and allows for single genes to produce multiple protein products, is frequently dysregulated in many cancers, including glioblastoma. However, along with non-synonymous mutations in the DNA, altered splicing mechanisms in cancers may produce novel antigens (so-called neoantigens) that distinguish cancer cells from healthy cells and can thus be targeted by the immune system. METHODS We developed a new computation pipeline (IRIS – Isoform peptides from RNA splicing for Immunotherapy targets Screening) that took bulk RNA-sequencing data from 23 glioblastoma patient tumor samples and predicted neoantigens that may arise from alternative splicing events. We prioritized predicted neoantigens that arose in HLA*A02:01 and HLA*A03:01 patients and selected 8 potential neoantigens to generate peptide:MHC Class 1 dextramers. We tested PBMCs and/or ex vivo expanded tumor infiltrating lymphocytes (TIL) from 6 of our glioblastoma patients against these dextramers, sorted for any neoantigen-reactive T cells, and performed single-cell RNAsequencing on the sorted population to determine the TCR sequence. RESULTS Among the 8 predicted neoantigens tested, 7 of the neoantigens were recognized by at least 1 patient’s T cells. 1 HLA*A03:01 epitope was recognized in 3 of the 4 HLA*A03:01 patients tested and this epitope was highly positive in an expanded TIL population, representing 1.7% of all CD3+ CD8+ cells. When we sorted for those neoantigen reactive T cells from the expanded TIL population and performed single-cell RNAsequencing, we found 325 unique T cell clonotypes, but the top 10 clonotypes represented 83.6% of all TCR clonotypes. The most frequent TCR clonotype represented 39.1% of the repertoire and suggests that clonal expansion of a select few TCR clones occurred within the tumor. CONCLUSIONS In total, our data indicates that neoantigens arising from alternative splicing events may represent a potential target for immunotherapy in glioblastoma.
Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux
Authors: Fakiha Siddiqui, Alfonso J Tafur, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Emily Bontekoe, Ahmed Kouta, Jawed Fareed
Journal: Blood (2019)
Low-Dose Triptolide Enhances Bromodomain Inhibitor JQ1-Induced Apoptosis of Acute Myeloid Leukemia Cells Via Down-Regulation of c-Myc Following RAS/MEK/ERK Inhibition
Authors: Bing Xu, Yuanfei Shi, Haijun Zhao, Yi Qiu
Journal: Blood (2019)
ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Authors: Håkan Mellstedt, Amineh Ghaderi, Johanna Aschan, Fariba Mozaffari, Ali Moshfegh, Birgitta Sander, Johan Schultz, Martin Norin, Thomas Olin, Elias Drakos, George Z. Rassidakis, Anders Österborg, Mohammad Hojjat-Farsangi
Journal: Blood (2019)
Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma
Authors: Cristina Panaroni, Keertik Fulzele, Rosemary Soucy, Cherrie Huang, Kenta Mukaihara, Shrikanta Chattopadhyay, Noopur S. Raje
Journal: Blood (2019)
ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells
Authors: Patrizia Sciancalepore, Barbara Castella, Chiara Riganti, Myriam Foglietta, Joanna Kopecka, Francesco Novelli, Giorgia Mandili, Ezio Tripoli, Nico Mitro, Donatella Caruso, Mario Boccadoro, Massimo Massaia
Journal: Blood (2016)
Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma
Authors: Eileen M Boyle, Faith E. Davies, Shayu Deshpande, Ruslana G. Tytarenko, Cody Ashby, Yan Wang, Christopher P. Wardell, Michael A Bauer, Sarah K Johnson, Carolina D. Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Maurizio Zangari, Louis Williams, Thierry Facon, Charles Dumontet, Bart Barlogie, Gareth Morgan, Brian A Walker
Journal: Blood (2019)
Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia
Authors: Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Luisa C A Koury, Raul Antônio Morais Melo, Rosane Bittencourt, Katia B Pagnano, Ricardo Pasquini, Elenaide C. Nunes, Evandro Maranhão Fagundes, Ana Beatriz F. Gloria, Fabio R. Kerbauy, Armand Keating, Martin S. Tallman, Raul Ribeiro, Richard Dillon, Arnold Ganser, Michael Heuser, Bob Löwenberg, Peter Valk, Miguel A. Sanz, Nancy Berliner, Antonio R. Lucena-Araujo, Eduardo M Rego
Journal: Blood (2019)
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job
Authors: Scott R. Evans, Robert Bigelow, Christy Chuang-Stein, Susan S. Ellenberg, Paul Gallo, Weili He, Qi Jiang, Frank Rockhold
Journal: Annals of Internal Medicine (2019)

Data monitoring committees (DMCs), or data and safety monitoring boards, protect clinical trial participants by conducting benefit-risk assessments during the course of a clinical trial. These evaluations may be improved by broader access to data and more effective analyses and presentation. Data monitoring committees should have access to all data, including efficacy data, at each interim review. The DMC reports should include graphical presentations that summarize benefits and harms in efficient ways. Benefit-risk assessments should include summaries that are consistent with the intention-to-treat principle and have a pragmatic focus. This article provides examples of graphical summaries that integrate benefits and harms, and proposes that such summaries become standard in DMC reports.
Fibrinogen Activates FAK to Promote the Colorectal Adenocarcinoma Growth
Authors: Balkrishan Sharma, Duaa Mureb, Sumit Murab, Leah A. Rosenfeldt, Brenton J Francisco, Alexander A Boucher, Rachel Cantrell, Jacob Mast, Matthew J. Flick, Patrick W Whitlock, Joseph S. Palumbo
Journal: Blood (2019)
Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
Authors: Nina D. Wagner-Johnston, Stephen J. Schuster, Sven de Vos, Gilles A. Salles, Wojciech Jurczak, Nishan Rajakumaraswamy, Guan Xing, Ajay K. Gopal
Journal: Blood (2019)
EXTH-71. IND-ENABLING CHARACTERIZATION OF ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR NEURO-ONCOLOGY
Authors: Varun Prabhu, Abed Rahman Kawakibi, Neel Madhukar, Mathew Garnett, Ultan McDermott, Cyril Benes, Robert Wechsler-Reya, Olivier Elemento, Martin Stogniew, Wolfgang Oster, Sharon DeMorrow, Joshua Allen
Journal: Neuro-Oncology (2019)

Abstract ONC201 is the first clinical bitopic antagonist of DRD2, an oncogenic receptor in brain and neuroendocrine tumors. ONC206, a derivative of ONC201 that shares the imipridone core structure, is also a bitopic DRD2 antagonist that exhibits enhanced non-competitive effects, high specificity, nanomolar potency, and disruption of DRD2 homodimers. Broad nanomolar efficacy of ONC206 (GI50 &lt; 78-889nM, CellTitre-Glo, 72h) was observed in &gt;1,000 GDSC cancer cell lines. Maximal ONC206 sensitivity was observed in pheochromocytoma, high-grade gliomas, neuroblastoma, medulloblastoma, sarcoma and cholangiocarcinoma cell lines exhibiting a DRD2+/DRD5- RNA expression signature. An exposure time of 48h at nanomolar concentrations was sufficient for maximal inhibition of tumor cell viability. ONC206 reduced the viability of normal human fibroblasts at higher doses (GI50 &gt; 5µM), suggesting a wide therapeutic window. Antitumor efficacy without body weight loss was observed with 50 mg/kg weekly oral ONC206 in a dopamine-secreting HuCCT1 cholangiocarcinoma subcutaneous xenograft model. Biodistribution studies in Sprague-Dawley rats revealed a ~12 µM plasma Cmax with a systemic terminal half-life of ~6 hours upon a single oral dose of 50 mg/kg. Additionally, 5–10 fold higher ONC206 concentrations were observed in adrenal gland, bile duct, brain and bone marrow relative to plasma. Nanomolar concentrations were also observed in the CSF above DRD2 antagonism thresholds, unlike ONC201. GLP toxicology studies with weekly oral ONC206 in Sprague-Dawley rats and beagle dogs revealed no dose-limiting toxicities. Mild and reversible decreased body weight and/or body weight gain with no effects on food consumption were observed at the highest evaluated dose in both species. The highest non-severely toxic dose (HNSTD) was ≥ 16.7 mg/kg in dogs and ≥ 50 mg/kg in rats that exceeds efficacious doses in preclinical models. Using standard allometric scaling, a 90 mg starting dose of ONC206 was selected for the first-in-human clinical trial in biomarker-defined adult recurrent CNS tumors.
Peripheral Blood to Marrow Collection White Cell Count Ratio As an Indicator of Harvest Quality and Transplant Outcomes in G-CSF-Primed Marrow Grafts
Authors: Rajat Kumar Agarwal, Rakesh Dhanya, Stalin Ramprakash, C P Raghuram, Pallavi Mehta, Deepa Trivedi, Shruthi Jayapal, Sandeep S, Lawrence Faulkner
Journal: Blood (2019)
Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction
Authors: Nicoletta Piroddi, Paola Pesce, Beatrice Scellini, Stefano Manzini, Giulia S Ganzetti, Ileana Badi, Michela Menegollo, Virginia Cora, Simone Tiso, Raffaella Cinquetti, Laura Monti, Giulia Chiesa, Steven B Bleyl, Marco Busnelli, Federica Dellera, Daniele Bruno, Federico Caicci, Annalisa Grimaldi, Roberto Taramelli, Lucia Manni, David Sacerdoti, Chiara Tesi, Corrado Poggesi, Simonetta Ausoni, Francesco Acquati, Marina Campione
Journal: Cardiovascular Research (2019)

Increased Ankyrin Repeat Domain 1 (ANKRD1) levels linked to gain of function mutations have been associated to total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans. The link between increased ANKRD1 level and cardiac structural and functional disease is not understood. To get insight into this problem, we have generated a gain of function ANKRD1 mouse model by overexpressing ANKRD1 in the myocardium.Ankrd1 is expressed non-homogeneously in the embryonic myocardium, with a dynamic nucleo-sarcomeric localization in developing cardiomyocytes. ANKRD1 transgenic mice present sinus venosus defect, which originates during development by impaired remodelling of early embryonic heart. Adult transgenic hearts develop diastolic dysfunction with preserved ejection fraction, which progressively evolves into heart failure, as shown histologically and haemodynamically. Transgenic cardiomyocyte structure, sarcomeric assembly, and stability are progressively impaired from embryonic to adult life. Postnatal transgenic myofibrils also present characteristic functional alterations: impaired compliance at neonatal stage and impaired lusitropism in adult hearts. Altogether, our combined analyses suggest that impaired embryonic remodelling and adult heart dysfunction in ANKRD1 transgenic mice present a common ground of initial cardiomyocyte defects, which are exacerbated postnatally. Molecular analysis showed transient activation of GATA4-Nkx2.5 transcription in early transgenic embryos and subsequent dynamic transcriptional modulation within titin gene.ANKRD1 is a fine mediator of cardiomyocyte response to haemodynamic load in the developing and adult heart. Increased ANKRD1 levels are sufficient to initiate an altered cellular phenotype, which is progressively exacerbated into a pathological organ response by the high ventricular workload during postnatal life. Our study defines for the first time a unifying picture for ANKRD1 role in heart development and disease and provides the first mechanistic link between ANKRD1 overexpression and cardiac disease onset.
Treatment of Recurrent Herpes Simplex
Authors: W. S. Inman
Journal: BMJ (1964)

those listed which give considerable force to the belief that this substance is a most useful therapeutic agent in the treatment of the iso- lated attack, both in the eye and on the skin.It would be a pity if your readers were led to the supposition that this substance should not at least be tried when dealing with such lesions.I would like to point out how important it is that the correct regimen is adhered to.In many cases my colleagues have approached me about the apparent ineffectiveness of the drug.On inquiry it has appeared that their notions of both the indications and administration have been somewhat astray.It should further be borne in mind that it is essential that treatment begin at the very earliest stage of the disease.It is hardly rational to expect much effect from any antiviral agent when the full tissue picture has developed.One might per- haps except the cornea and its own rather individual circumstances.-Iam, etc., Brighton.
Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Authors: Timothy J Voorhees, Natalie S Grover, Anne Beaven, Steven I Park, J. Kaitlin Morrison, Catherine Joyce Arago Cheng, Spencer Laing, Gianpietro Dotti, Barbara Savoldo, Jonathan S Serody
Journal: Blood (2019)